Millie
your market intelligence analyst
Search Results
100 results
Your search is now limited to «Thyroid Cancer» expert search.
ClinicalTrials.gov 10/16/2019 08:28
The I-131 WBS has high specificity to detect recurrence (50 to 60% in papillary thyroid carcinoma and 64 to 67% in follicular thyroid carcinoma) (3,4.
More from ClinicalTrials.gov:
News-Medical.net 10/15/2019 18:07
In the case of low-risk treated thyroid cancer, some patients may be insisting on unduly intensive surveillance in the form of diagnostic scans to detect recurrence, without clear evidence for any benefit from the same, says a new study published in the Journal ...
More from News-Medical.net:
Finally, additional thyroid tissue samples were collected to verify the results above.
More from International Journal of COPD:
Cancer Network 10/07/2019
Although the combination of the VEGF receptor inhibitor pazopanib and the MEK inhibitor trametinib was tolerated by patients with differentiated thyroid cancer (DTC), it did not meet the response rate target, according to the results of a phase 1 study published in Clinical Cancer Research.
More from Cancer Network:
FeedNavigator (EU) 10/05/2019 09:07
The US Preventive Services Task Force recommends against screening for thyroid cancer in the general, asymptomatic adult population, as such screening would result in harms that outweigh any potential benefits.
More from FeedNavigator (EU):
Annals of Oncology 09/30/2019 20:00
Abstract. Background. To date, no targeted therapy is approved for patients with RET-altered cancers. LOXO-292 is a highly selective RET inhibitor with activity across known oncogenic RET fusions and mutations. Based on initial data from LIBRETTO-001, LOXO-292 received FDA Breakthrough Designation for the treatment of RET fusion+ non-small cell lung cancer (NSCLC), RET fusion+ thyroid cancer and RET-mutant medullary thyroid cancer (MTC). Methods. The LIBRETTO-001 global phase I/II study (87 sites, 16 countries) enrolled patients with advanced RET fusion+ cancers and RET-mutant MTC (NCT03157128). LOXO-292 was dosed orally in 28-day cycles. Phase I established the RP2D. Phase II enrolled patients in one of six cohorts based on tumor type, RET al.
Targeted Oncology 09/17/2019 12:48
In an interview with Targeted Oncology , Chai discussed the latest treatment advancements for thyroid cancer that he has seen over the past few years and how he sees quality of life improving for patients with advanced subtypes of thyroid cancer.
More from Targeted Oncology:
Healio News 09/15/2019 07:00
Although Sinclair noted that this procedure is best used for treatment of benign noncancerous thyroid nodules, there is potential for treatment of thyroid cancer, but that would likely be effective for only a small population of patients.
More from Healio News:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications